Stratasys Dental's Negar Movahed says they're 'open for partnerships' in dental 3D printing market

Stratasys Dental, the dental-focused division of Stratasys Ltd., is signaling an open partnership strategy in the dental 3D printing market, according to Global Director of Product Lines – Dental Negar Movahed, who spoke at RAPID+TCT 2026. The company’s flagship product remains the TrueDent monolithic, polychromatic denture solution, which is Stratasys’ first Class IIa medical device. TrueDent uses PolyJet technology to print gingiva and teeth in a single build from one resin with multiple shades (Cyan, Magenta, Yellow, White), eliminating the bonding interface that is a common failure point in conventional dentures. Movahed emphasized that the company is building automation into every step of the workflow, with additional software capabilities expected in the next year, and that Stratasys Dental serves both small labs and large automated facilities.

This announcement lands in a dental AM market that generated $5.2 billion in revenue in 2024, nearly one-third of the total additive manufacturing market, and is forecast to nearly double to $9.6 billion by 2033. Stratasys Dental’s open-for-partnerships stance reflects a strategic pivot in a segment where the competitive landscape is increasingly defined by workflow integration rather than raw printer specs. The company’s TrueDent solution competes directly with DLP-based dental workflows from companies like Carbon, Formlabs, and Desktop Health, but differentiates on aesthetics via PolyJet’s multi-material capability and on throughput — Movahed noted that PolyJet can print 32 complete multi-shade arches in a single build, versus 15-20 denture bases on a DLP printer. By positioning itself as open to partnerships, Stratasys Dental is signaling that it sees value in collaborating with software providers, material suppliers, and lab automation integrators rather than trying to own the entire stack alone.

For dental labs evaluating their AM strategy, the practical takeaway is that Stratasys Dental is prioritizing workflow automation and regulatory rigor over raw speed or cost-per-part. The TrueDent solution’s Class IIa medical device classification means labs adopting it inherit a validated regulatory pathway, which reduces their own qualification burden. The open-partnerships language suggests Stratasys Dental is willing to integrate with third-party design software and post-processing equipment, which could lower switching costs for labs already invested in exocad or 3Shape workflows. The company’s 2027 product launch, which Movahed hinted will further enhance aesthetics, will be the next concrete milestone to watch.